Piramal Pharma Solutions (PPS), a contract development and manufacturing organization (CDMO) and part of Piramal Pharma Limited, has made a multi-million-dollar investment toward creating a high-throughput screening facility that will enhance the current in-vitro biology capabilities at its drug discovery services site in Ahmedabad, India. Executives within the company say that the new expansion—which is anticipated to go live by Q3 of this year—will considerably add to the primary and secondary screening capabilities of compounds prepared at this specific location.
Specifically, the CDMO’s new investment is expected to provide improvements to drug discovery cycle times. New personnel with experience in biology services will also be brought on board, alongside the current staff.
The new high-throughput screening technology enables PPS to evaluate and screen 1000 compounds per week using various assay platform technologies, such as a fluorescent imaging plate reader (FLIPR), TR-FRET/HTRF, fluorescence polarization (FP), absorbance, luminescence/electrochemiluminescence (ECL), alpha screen, lantha screen, flow cytometry and high-content imaging. These platforms will be applicable to various targets, including G-protein-coupled receptors (GPCRs) and kinase-targeted therapies to name a few.